Enter your keyword

Efficiently Creating Value with Innovative Science

Press Releases

Date Title and Summary Additional Formats
Toggle Summary OXiGENE to Present at 3rd International Symposium on Targeted Anticancer Therapies
OXiGENE to Present at 3rd International Symposium on Targeted Anticancer Therapies WALTHAM, Mass.--(BUSINESS WIRE)--March 4, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a leading developer of biopharmaceutical compounds designed to target aberrant blood vessels within solid tumor cancers and
View HTML
Toggle Summary OXiGENE Announces Sale of $15 Million of Common Stock
OXiGENE Announces Sale of $15 Million of Common Stock WALTHAM, Mass.--(BUSINESS WIRE)--March 4, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) today announced that the Company will receive gross proceeds of $15 million from the sale of 3,336,117 shares of its common stock, pursuant to OXiGENE's
View HTML
Toggle Summary OXiGENE to Present at Wells Fargo Securities 2005 HealthCare Conference: March 2nd Presentation Available via Live Webcast
OXiGENE to Present at Wells Fargo Securities 2005 HealthCare Conference: March 2nd Presentation Available via Live Webcast WALTHAM, Mass.--(BUSINESS WIRE)--March 1, 2005--OXiGENE, Inc. (NASDAQ:OXGN, XSSE:OXGN), a leading developer of biopharmaceutical compounds designed to target aberrant blood
View HTML
Toggle Summary OXiGENE Reports Fourth-Quarter and Year-End 2004 Financial Results
OXiGENE Reports Fourth-Quarter and Year-End 2004 Financial Results WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 25, 2005--Accomplishments in 2004: Initiated two new clinical oncology trials with CA4P; CA4P now studied in seven clinical oncology trials Initiated a Phase II trial of CA4P in myopic macular
View HTML
Toggle Summary OXiGENE to Participate on Distinguished Anti-angiogenesis Panel at BIO CEO & Investor Conference
OXiGENE to Participate on Distinguished Anti-angiogenesis Panel at BIO CEO & Investor Conference WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 22, 2005--OXiGENE Inc, (NASDAQ: OXGN, SSE: OXGN) today announced that Dai Chaplin, Chief Scientific Officer of OXiGENE, will participate in a focus session entitled
View HTML
Toggle Summary OXiGENE to Present at Roth Capital Partners 17th Annual OC Conference: February 22nd Presentation Available via Live Webcast
OXiGENE to Present at Roth Capital Partners 17th Annual OC Conference: February 22nd Presentation Available via Live Webcast WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 18, 2005--OXiGENE, Inc. (NASDAQ: OXGN) (XSSE: OXGN), today announced that President and Chief Executive Officer Fred Driscoll will
View HTML
Toggle Summary OXiGENE's Lead Compound CA4P Enhances the Anti-Tumor Activity of Avastin in Pre-clinical Studies
OXiGENE's Lead Compound CA4P Enhances the Anti-Tumor Activity of Avastin in Pre-clinical Studies Data Presented at International Symposium on Anti-Angiogenic Agents Conference in La Jolla WALTHAM, Mass., Feb 14, 2005 (BUSINESS WIRE) -- OXiGENE, Inc. (Nasdaq: OXGN, XSSE: OXGN) announced today that
View HTML
Toggle Summary OXiGENE Sets Conference Call and Webcast for Fourth Quarter and Full-Year 2004 Results
OXiGENE Sets Conference Call and Webcast for Fourth Quarter and Full-Year 2004 Results WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 9, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) invites the public to listen to a live audio webcast of the Company's fourth quarter and full-year 2004 financial results
View HTML
Toggle Summary OXiGENE's CA4P Demonstrates Anti-tumor Activity in Preclinical Retinoblastoma Model- Study Published in Investigative Ophthalmology & Visual Science -
OXiGENE's CA4P Demonstrates Anti-tumor Activity in Preclinical Retinoblastoma Model- Study Published in Investigative Ophthalmology & Visual Science - WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 4, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) announced today the publication of a preclinical study using
View HTML
Toggle Summary OXiGENE Announces Corporate Goals for 2005: Company Plans to Move CA4P into Later-stage Clinical Studies in Two Cancer Indications in 2005
OXiGENE Announces Corporate Goals for 2005: Company Plans to Move CA4P into Later-stage Clinical Studies in Two Cancer Indications in 2005 WALTHAM, Mass.--(BUSINESS WIRE)--Jan. 7, 2005--OXiGENE, Inc. (Nasdaq: OXGN, XSSE: OXGN), developing novel small-molecule therapeutics to treat cancer and
View HTML